This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
The combination of bendamustine, bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Jonathan W. Friedberg,*1 Julie M. Vose,2 Jennifer L. Kelly,1 Faith Young,1 Steven H. Bernstein,1 Derick Peterson,1 Lynn Rich,1 Susan Blumel,2 Nicole K. Proia,1 Jane Liesveld,1 Richard I.Fisher,1 James O. Armitage,2 Steven Grant3 and John P. Leonard4 1James P. Wilmot Cancer Center, University of Rochester; 2University of Nebraska Medical Center, 3Virginia Commonwealth University Massey Cancer Center, and 4Cornell Weill Medical Center. Presented in part at the American Society of Hematology Annual Meeting 2009, New Orleans, LA. Correspondence: Jonathan Friedberg, MD, James P. Wilmot Cancer Center
University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642;
1. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23(33):8447-8452.
2. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511-518.
3. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23(22):5019-5026.
4. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732.
5. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-1992.
6. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111(12):5530-5536.
7. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918-3927.
8. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26(2):204-210.
9. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. ;116(1):106-114.
10. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(27):4473-4479.
11. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(15):3383-3389.
12. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first line treatment of patients with advanced follicular, indolent and mantle cell lymphomas: final results of a randomized phase III study of the StiL. Blood. 2009;114:168-169.
13. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867-4874.
14. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or
For personal use only.on November 16, 2018. by guest www.bloodjournal.orgFrom
refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27(30):5023-5030.
15. Leonard JP, Furman RR, Cheung Y-KK, et al. Phase I/II trial of bortezomib + CHOP-Rituximab in diffuse large B cell and mantle cell lymphoma: Phase I results. Blood. 2005;106:146a.
16. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8(12):1935-1937.
17. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
18. Rosato RR, Kolla SS, Hock SK, et al. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem. 26;285(13):10064-10077.
19. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
20. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. ;10(1):21-27.
21. Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine and rituxmab in patients with relapsed or refractory follicular lympohma: encouraging activith in the phase 2 VERTICAL study. Blood. 2009;114(22):384-385.
22. Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol. 2009;146(6):652-655.
23. Moosmann P, Heizmann M, Kotrubczik N, Wernli M, Bargetzi M. Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma. ;51(1):149-152.
24. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784-4790.
25. Pour L, Adam Z, Buresova L, et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2009;9(2):151-153.
26. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115(1):229-232.
27. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
29. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24(13):2105-2112.
30. Friedberg JW. The emerging role of bendamustine in follicular lymphoma. Leuk Lymphoma. 2009;50(3):317-318.
For personal use only.on November 16, 2018. by guest www.bloodjournal.orgFrom
Figure 1. Waterfall plot of best response following therapy. Three of the treated patients (n=30) are not included due to rapid clinical progression without additional imaging (n=2), and one death prior to re-staging evaluation. Figure 2. Progression Free Survival. Kaplan-Meier estimate progression free survival, with number at risk, for: A) all treated patients (n=30); B) Follicular Lymphoma patients (n=15) C) Mantle Cell Lymphoma patients (n=7).
For personal use only.on November 16, 2018. by guest www.bloodjournal.orgFrom
doi:10.1182/blood-2010-11-314708Prepublished online January 14, 2011;
Armitage, Steven Grant and John P. LeonardPeterson, Lynn Rich, Susan Blumel, Nicole K. Proia, Jane Liesveld, Richard I. Fisher, James O. Jonathan W. Friedberg, Julie M. Vose, Jennifer L. Kelly, Faith Young, Steven H. Bernstein, Derick with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaThe combination of bendamustine, bortezomib and rituximab for patients
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requestsInformation about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprintsInformation about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtmlInformation about subscriptions and ASH membership may be found online at:
digital object identifier (DOIs) and date of initial publication. indexed by PubMed from initial publication. Citations to Advance online articles must include final publication). Advance online articles are citable and establish publication priority; they areappeared in the paper journal (edited, typeset versions may be posted when available prior to Advance online articles have been peer reviewed and accepted for publication but have not yet
Copyright 2011 by The American Society of Hematology; all rights reserved.Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of
For personal use only.on November 16, 2018. by guest www.bloodjournal.orgFrom